Skip to main content

CSI Laboratories PD-L1 Expression Assay

CSI Laboratories, a private national reference laboratory specializing in cancer diagnostics, has launched a PD-L1 (programmed death-ligand 1) immunohistochemical protein expression assay, which can be used to potentially predict a patient's response to several commercially available PD-1/PD-L1 inhibitor therapies. More specifically, the assay provides a specimen's PD-L1 tumor cell reactivity score, which can be used to identify patients who are more likely to respond to certain PD-1/PD-L1 inhibitor therapies.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.